Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFCPG0)

• Drug Name: CAR-T cells targeting GD2 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Glioma	2A00.0	Phase 1/2	[1]
Lung cancer	2C25.0	Phase 1/2	[2]
Glioblastoma multiforme	2A00.0	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMFCPG0

Molecule-Related Drug Atlas

Drug(s) Targeting Ganglioside GD2 (GD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[4]
Anti-GD2 CART	DMVQHBK	Neuroblastoma	2D11.2	Phase 2	[5]
Hu3F8 mAb	DM9MKQ5	Neuroblastoma	2D11.2	Phase 2	[6]
APN301	DMGNFBC	Neuroblastoma	2D11.2	Phase 2	[7]
4SCAR-GD2	DMEGSU5	Tumour	2A00-2F9Z	Phase 1/2	[8]
CAR-T cells targeting CD2	DMJVENR	Cervical cancer	2C77.0	Phase 1/2	[9]
GD2-CART01	DM5VF04	Neuroblastoma	2D11.2	Phase 1/2	[10]
IC9-GD2-CD28-OX40	DMRYHWA	Neuroblastoma	2D11.2	Phase 1	[11]
Anti-GD2 T-cells (1RG-CART)	DMBVUFL	Neuroblastoma	2D11.2	Phase 1	[12]
Anti-GD2-CAR engineered T cells	DMCNFZG	Neuroblastoma	2D11.2	Phase 1	[13]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[4]
Anti-GD2 CART	DMVQHBK	Neuroblastoma	2D11.2	Phase 2	[5]
Hu3F8 mAb	DM9MKQ5	Neuroblastoma	2D11.2	Phase 2	[6]
APN301	DMGNFBC	Neuroblastoma	2D11.2	Phase 2	[7]
4SCAR-GD2	DMEGSU5	Tumour	2A00-2F9Z	Phase 1/2	[8]
CAR-T cells targeting CD2	DMJVENR	Cervical cancer	2C77.0	Phase 1/2	[9]
GD2-CART01	DM5VF04	Neuroblastoma	2D11.2	Phase 1/2	[10]
IC9-GD2-CD28-OX40	DMRYHWA	Neuroblastoma	2D11.2	Phase 1	[11]
Anti-GD2 T-cells (1RG-CART)	DMBVUFL	Neuroblastoma	2D11.2	Phase 1	[12]
Anti-GD2-CAR engineered T cells	DMCNFZG	Neuroblastoma	2D11.2	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ganglioside GD2 (GD2)	TT80ARU	NOUNIPROTAC	CAR-T-Cell-Therapy	[2]

References

• [1] ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
• [2] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [3] ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
• [4] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [5] ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of Apeiron Biologics.
• [8] ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
• [9] ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
• [10] ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
• [11] ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
• [12] ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
• [13] ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors